Use of a Physiologically Based Pharmacokinetic Model for Rats to Study the Influence of Body Fat Mass and Induction of CYP1A2 on the Pharmacokinetics of TCDD

Claude Emond; Linda S. Birnbaum; Michael J. DeVito

doi:10.1289/ehp.8805

journal article Sep 01, 2006

Use of a Physiologically Based Pharmacokinetic Model for Rats to Study the Influence of Body Fat Mass and Induction of CYP1A2 on the Pharmacokinetics of TCDD

Claude Emond Linda S. Birnbaum Michael J. DeVito

Environmental Health Perspectives Vol. 114 No. 9 pp. 1394-1400 · American Chemical Society (ACS)

View at Publisher Save 10.1289/ehp.8805

Topics

No keywords indexed for this article. Browse by subject →

References

47

[1]

10.1067/mcp.2002.126408

[2]

10.1007/bf00293624

[3]

10.1016/0015-6264(75)90002-4

[4]

10.1006/taap.1996.8067

[5]

10.1111/j.1539-6924.1993.tb00726.x

[6]

Cytochromes P450 and metabolism of xenobiotics

P. Anzenbacher, E. Anzenbacherová

Experientia 10.1007/pl00000897

[7]

10.1038/sj.jea.7500370

[8]

10.1021/es960192r

[9]

10.1006/taap.1995.1069

[10]

10.1006/taap.1995.1068

[11]

10.2174/1389200013338676

[12]

10.1289/ehp.5831

[13]

10.1016/0300-483x(95)03040-m

[14]

10.1006/taap.1999.8720

[15]

10.1093/toxsci/61.2.241

[16]

10.1093/toxsci/kfh117

[17]

10.1289/ehp.8016

[18]

10.1080/009841096161708

[19]

Hakk H "Comparison of overall metabolism of 2,3,7,8-TCDD in CYP1A2 (−/−) knockout and C57BL/6N parental strains on mice" Organohalogen Compounds (2002)

[20]

10.1016/0041-008x(91)90145-5

[21]

10.1006/taap.1996.0004

[22]

Lakshmanan MR "Studies on the mechanism of absorption and distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat" J Pharmacol Exp Ther (1986)

[23]

10.1080/00984100290071829

[24]

10.1038/sj.jea.7500201

[25]

10.1080/009841099157584

[26]

10.1016/s0045-6535(01)00100-x

[27]

10.1006/faat.1994.1069

[28]

Pinsky PF "A model to evaluate past exposure to 2,3,7,8-TCDD" J Expo Anal Environ Epidemiol (1998)

[29]

10.1289/ehp.7305241

[30]

10.1111/j.1600-0773.1990.tb00712.x

[31]

10.1007/bf02004514

[32]

10.1016/0041-008x(76)90001-6

[33]

10.1016/s0048-9697(01)00729-x

[34]

10.1006/bbrc.1997.6389

[35]

10.1006/taap.1998.8466

[36]

10.1016/s0003-9861(02)00366-1

[37]

Staskal DF "Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals" Toxicol Sci 2005 (2005)

[38]

10.1093/aje/154.5.451

[39]

Steiner EC Rey TD McCroskey PS 1990. Reference Guide for Simusolv. Midland MI:Dow Chemical Co.

[40]

10.1006/taap.1993.1218

[41]

10.1016/s0045-6535(98)00249-5

[42]

10.1038/sj.jea.7500140

[43]

10.1006/faat.1996.0090

[44]

10.1006/taap.1998.8595

[45]

10.1093/toxsci/56.1.49

[46]

10.1006/taap.1997.8242

[47]

10.1006/faat.1993.1129

Cited By

66

Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses

Laura N. Vandenberg, Theo Colborn · 2012

Endocrine Reviews

The effect of dose on 2,3,7,8-TCDD tissue distribution, metabolism and elimination in CYP1A2 (-/-) knockout and C57BL/6N parental strains of mice

Heldur Hakk, Janet J. Diliberto · 2009

Toxicology and Applied Pharmacology

Metrics

66

Citations

47

References

Details

Published: Sep 01, 2006
Vol/Issue: 114(9)
Pages: 1394-1400

Authors

C

Claude Emond

National Research Council, National Academy of Sciences, Washington, DC, USA; National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA; Environmental and Occupational Health Department, Medicine Faculty, University of Montreal, Montreal, Quebec, Canada

L

Linda S. Birnbaum

National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA

M

Michael J. DeVito

National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA

Cite This Article

Claude Emond, Linda S. Birnbaum, Michael J. DeVito (2006). Use of a Physiologically Based Pharmacokinetic Model for Rats to Study the Influence of Body Fat Mass and Induction of CYP1A2 on the Pharmacokinetics of TCDD. Environmental Health Perspectives, 114(9), 1394-1400. https://doi.org/10.1289/ehp.8805

Use of a Physiologically Based Pharmacokinetic Model for Rats to Study the Influence of Body Fat Mass and Induction of CYP1A2 on the Pharmacokinetics of TCDD

You May Also Like